[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
May 2, 2007

FDA Responds to Institute of Medicine Drug Safety Recommendations—In Part

Author Affiliations
 

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, and Center for Health Studies, Group Health, Seattle (Dr Psaty); and University of Wisconsin Law and Medical Schools, Madison (Ms Charo).

JAMA. 2007;297(17):1917-1920. doi:10.1001/jama.297.17.1917

The withdrawal of rofecoxib in September 2004 and the reports of health risks associated with several other drugs1 have raised questions about the integrity of the US drug safety system. In response, and at the request of the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA), the Institute of Medicine (IOM) issued a comprehensive review and set of recommendations for reforms.2 The FDA has taken the unusual step of providing a detailed, public response.3 The FDA's new initiatives and its responsiveness to the IOM report represent incremental progress that offers insights into FDA's culture and perhaps glimpses at the future of drug safety.

First Page Preview View Large
First page PDF preview
First page PDF preview
×